top of page

A Transformative Breakthrough

A tested, proprietary chemistry platform that cuts costs and improves product performance in a growth industry

Corporate Profile : Summary

  • We design, build and sell proprietary Point-of-Care (PoC) diagnostic products for respiratory diseases

  • Our PoC diagnostics and results are conducted at the location of patient sample collection

  • Gemina advances are a 'quantum leap' in Lateral Flow Assays

  • We aim to democratize diagnostics, bringing the reality of precision diagnostics to every health system in the world. Providing lab accuracy in affordable formats to doctors, health professionals, clinics and homes in every part of the globe

The Gemina Board

John Davies.jpg

John Davies

Independent Chairman

Bola Grace.jpg

Bola Grace

Independent Director

Brian Firth.jpg

Brian Firth

Chief Executive Officer

Rob Greene.jpg

Rob Greene

Chief Technology Officer

Martin Cronin.jpg

Martin Cronin

Independent Director

Martha Najib.jpg

Martha Najib

Independent Director

Gemina Labs News

Stay in touch with the latest news from Gemina Labs:

Corporate and Regulatory News is released to the press via Accesswire and can be accessed via mainstream finance news services such as Yahoo Finance. 

Our own news page is where you'll find corporate and regulatory news, appointments, organisation & people, operations and product news.

You'll also find us on LinkedIn.

  • LinkedIn

Get our news and presentations straight to your inbox

We won't bombard you, sell or share your data - and you can unsubscribe at any time

Thanks for subscribing

Presentations and Documentation

11 April 2024

Financial Statement Request Form

11 April 2024

Notice of Meeting and Management Information Circular

01 March 2023

Investor Presentation March 2023

Calendar Pages

Financial Calendar

31 May 2023

Year End (31st January) Results published

30 June 2023

Q1 (30th April) Results published

30 September 2023

Q2 (31st July) Results published

31 December 2023

Q3 (31st October) Results published

31 May 2024

Year End (31st January) Results published


For all investor enquiries, please email

bottom of page